Status:

COMPLETED

An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

Lead Sponsor:

Eli Lilly and Company

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study. The study pr...

Eligibility Criteria

Inclusion

  • Have completed the final active treatment in study JADV (NCT01710358), JADZ (NCT01711359), JADX (NCT01721057), JADW (NCT01721044), JADA (NCT01185353) or JAGS (NCT02265705)

Exclusion

  • Have significant uncontrolled cerebro-cardiovascular (eg, myocardial infarction \[MI\], unstable angina, unstable arterial hypertension, severe heart failure, or cerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neuropsychiatric disorders, or abnormal laboratory values that developed during a previous baricitinib study that, in the opinion of the investigator, pose an unacceptable risk to the participant if investigational product continues to be administered
  • Have a known hypersensitivity to baricitinib or any component of this investigational product
  • Had investigational product permanently discontinued at any time during a previous baricitinib study
  • Had temporary investigational product interruption at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for participation in the study
  • Have any other condition that, in the opinion of the investigator, renders the participant unable to understand the nature, scope, and possible consequences of the study or precludes the participant from following and completing the protocol

Key Trial Info

Start Date :

June 27 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 12 2020

Estimated Enrollment :

2877 Patients enrolled

Trial Details

Trial ID

NCT01885078

Start Date

June 27 2013

End Date

November 12 2020

Last Update

April 25 2022

Active Locations (408)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 102 (408 locations)

1

Arizona Arthritis & Rheumatology Research, PLLC

Glendale, Arizona, United States, 85306

2

Arizona Arthritis & Rheumatology Associates, P. C.

Mesa, Arizona, United States, 85202

3

Sun Valley Arthritis Center, LTD

Peoria, Arizona, United States, 85381

4

Arizona Research Center

Phoenix, Arizona, United States, 85053